


# CIPAC STATUS REPORT

28/06/2005



## 0111 Chloridazon

---

Allocated to CS  
1979 allocated to E  
1985 allocated to D

CIPAC methods published in :

CIPAC D, p. 31  
CIPAC H, p. 76

**CIPAC** 19th meeting, June 1975 in Oeiras

Information Sheet will be sent out.

**CIPAC** 20th meeting, June 1976 in Wädenswil

Information Sheet to be sent out.

**CIPAC** 21st meeting, June 1977 in Braunschweig

Collaborative study under way.

**CIPAC** 22nd meeting, June 1978 in Versailles

Collaborative work will start soon.

**CIPAC** 23rd meeting, June 1979 in Baltimore

Allocated to E

**CIPAC** 24th meeting, May 1980 in Salobrena

The product is important. Dr Batora should be asked about the situation.

**CIPAC** 26th meeting, May 1982 in Rome

Dr Gimeno presented a HPLC method (CIPAC/3050/m) and said that PACE could have a preliminary study. When the results were good an international collaborative study could be initiated. Dr Batora should be asked if he could agree that PACE would conduct this study.

**CIPAC** 29th meeting, September 1985 in Copenhagen

A preliminary study had been carried out by DAPA with a HPLC method. DAPA was prepared to take over this compound. Mrs Hitos had no objections. So chloridazon was allocated to DAPA.

# CIPAC STATUS REPORT

28/06/2005

**CIPAC** 30th meeting, June 1986 in Vienna

Mr Pawliczek presented the results of a collaborative study with a HPLC method carried out by DAPA (CIPAC/3333). The final version of the method would be completed with an IR identification test.

Decision The HPLC method for chloridazon technical and formulations, CIPAC/3332, was adopted as full CIPAC method.

**CIPAC** 41st meeting, June 1997 in Roskilde

Mr Pawliczek reported the results of a validation test for the HPLC method (published in CIPAC D) according to GLP for the extension of the scope of the method to WG formulations. Mr Declercq and Mr Køppen had some concerns in accepting a general provision for extending the applicability of methods to formulations other than tested without results from a collaborative study. Because of the similarity of WP and WG formulations and because the content of the a.i. was in the same range the validation study was regarded as sufficient. Mr Martijn will prepare a new paper on the comparability of formulation types.

Decision The HPLC method for chloridazon has been accepted as full CIPAC method for WG formulations in addition to the existing full CIPAC methods for technical material and WP and SC formulations.